Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NKTR

Nektar Therapeutics

Sep 12 • 04:00PM ET

48.68

+1.48 3.14 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF LFSC SCHA PINK FESM PRFZ SURI ITOT SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.72	Insider Own	2.23%	Shs Outstand	19.02M	Perf Week	21.15%
Market Cap	925.89M	Forward P/E	-	EPS next Y	-12.18	Insider Trans	-14.01%	Shs Float	18.60M	Perf Month	89.27%
Enterprise Value	926.72M	PEG	-	EPS next Q	-2.86	Inst Own	45.71%	Short Float	6.00%	Perf Quarter	455.71%
Income	-122.27M	P/S	12.36	EPS this Y	-32.82%	Inst Trans	13.85%	Short Ratio	0.52	Perf Half Y	5870.08%
Sales	74.93M	P/B	-	EPS next Y	-5.42%	ROA	-44.39%	Short Interest	1.12M	Perf YTD	248.96%
Book/sh	-1.94	P/C	5.26	EPS next 5Y	-17.69%	ROE	-440.80%	52W High	50.53 -3.66%	Perf Year	161.72%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-93.69%	52W Low	0.43 11168.52%	Perf 3Y	-14.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	82.58%	Volatility	11.92% 8.34%	Perf 5Y	-82.85%
Dividend TTM	-	EV/Sales	12.37	EPS Y/Y TTM	35.55%	Oper. Margin	-185.67%	ATR (14)	3.22	Perf 10Y	-70.79%
Dividend Ex-Date	-	Quick Ratio	2.61	Sales Y/Y TTM	-19.56%	Profit Margin	-163.17%	RSI (14)	84.23	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	2.61	EPS Q/Q	21.50%	SMA20	43.48%	Beta	-1.16	Target Price	96.17
Payout	-	Debt/Eq	-	Sales Q/Q	-52.42%	SMA50	74.40%	Rel Volume	0.39	Prev Close	47.20
Employees	61	LT Debt/Eq	-	Earnings	Aug 07 AMC	SMA200	225.08%	Avg Volume	2.16M	Price	48.68
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.56% 17.77%	Trades		Volume	849,600	Change	3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5

Show Previous Ratings

Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
06:15PM	Loading…
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Loading…
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Loading…
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Mar-12-25 08:30PM	Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
07:00PM	Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates (Zacks)
06:12PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-05-25 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-27-25 10:59AM	Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata (Clinical Trials Arena)
Feb-26-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata (PR Newswire) -10.38%
Feb-24-25 07:00AM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th (PR Newswire) -9.35%
07:00AM	Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus (PR Newswire)
Feb-10-25 07:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Feb-07-25 09:35AM	Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround (Zacks)
Jan-31-25 09:55AM	Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-10-25 07:00AM	Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire) -9.65%
Jan-07-25 09:24AM	Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-07-24 12:00PM	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (PR Newswire)
Nov-18-24 03:30PM	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence (PR Newswire)
Nov-08-24 02:30AM	Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook (GuruFocus.com)
Nov-07-24 05:40PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:36PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire)
10:15AM	Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 06:00PM	Nektar Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-05-24 10:34AM	Nektar Therapeutics to sell Alabama facility to Ampersand (Pharmaceutical Technology) +5.26%
Nov-04-24 01:44PM	Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential (Benzinga) +8.13%
08:30AM	Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama (PR Newswire)
Oct-31-24 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-29-24 09:00AM	Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases (PR Newswire) -6.62%
Oct-17-24 12:07PM	Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (PR Newswire) +5.07%
Sep-25-24 03:30AM	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 (PR Newswire)
Sep-03-24 09:00AM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire)
Aug-13-24 12:00PM	What Makes Nektar (NKTR) a New Buy Stock (Zacks)
Aug-09-24 10:58AM	Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top (Zacks) -8.26%
Aug-08-24 05:55PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:49PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.22% -5.51%
Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.99%
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM
Wilson Mark Andrew	Chief Legal Officer	Dec 23 '24	Sale	0.90	33,402	30,062	351,892	Dec 26 07:04 PM
Wilson Mark Andrew	Chief Legal Officer	Dec 24 '24	Sale	0.89	16,560	14,738	335,332	Dec 26 07:04 PM
Wilson Mark Andrew	Officer	Dec 24 '24	Proposed Sale	0.89	16,560	14,801		Dec 26 09:35 AM
Wilson Mark Andrew	Officer	Dec 23 '24	Proposed Sale	0.90	33,402	29,898		Dec 23 03:21 PM
Zalevsky Jonathan	Chief R&D Officer	Dec 19 '24	Sale	0.94	51,115	48,048	326,904	Dec 20 08:33 PM
ROBIN HOWARD W	President & CEO	Dec 18 '24	Sale	0.99	85,035	84,185	1,110,675	Dec 19 09:08 PM
ROBIN HOWARD W	President & CEO	Dec 17 '24	Sale	1.01	46,995	47,465	1,195,710	Dec 19 09:08 PM
Zalevsky Jonathan	Officer	Dec 19 '24	Proposed Sale	0.94	51,115	48,063		Dec 19 03:12 PM
ROBIN HOWARD W	Officer	Dec 18 '24	Proposed Sale	0.99	85,035	84,244		Dec 18 04:17 PM
ROBIN HOWARD W	Officer	Dec 17 '24	Proposed Sale	1.01	46,995	47,338		Dec 17 03:29 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 19 '24	Sale	1.01	7,785	7,863	243,019	Nov 20 08:37 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 19 '24	Sale	1.01	6,407	6,471	218,856	Nov 20 08:36 PM
ROBIN HOWARD W	President & CEO	Nov 19 '24	Sale	1.01	16,278	16,441	832,080	Nov 20 08:36 PM
Zalevsky Jonathan	Officer	Nov 19 '24	Proposed Sale	1.01	7,785	7,878		Nov 19 04:10 PM
Wilson Mark Andrew	Officer	Nov 19 '24	Proposed Sale	1.01	6,407	6,483		Nov 19 03:28 PM
ROBIN HOWARD W	Officer	Nov 19 '24	Proposed Sale	1.01	16,278	16,472		Nov 19 03:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience